Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
APT Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A recipient of a single or double lung transplant (including heart-lung transplant)
Age 18 years or older
Able to produce a forced expiratory volume in one second (FEV1) of greater than one liter at randomization
Eligible subjects must be enrolled within 70 days after receiving a lung transplant
Clinical status sufficiently stable to enable routine post-transplant bronchoscopy with bronchoalveolar lavage (BAL) and chest X-ray (or equivalent i.e., chest computerized tomogram (CT)) prior to screening
You may not be if
Lung re-transplantation
Documented allergy to propylene glycol and/or cyclosporine
Documented respiratory or anastomotic infections unless on appropriate antimicrobial therapy with evidence of clinical response
Women who are pregnant, wishing to become pregnant, or unwilling to use appropriate birth control to avoid becoming pregnant
Women who are breastfeeding
Clinically significant bronchial stenosis unresponsive to dilation and/or stenting
Malignancies diagnosed within one year prior to screening (with the exception of non-melanomatous skin cancers)
Clareo Health | Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation
